홈

Invited Speakers & Chairpersons

검색

Day 2 – June 26 (Fri)

Breakfast with Master 1 Beyond the Clinical Trial Data : Impact of Real-World Experience of ZEPOSIA® June 26 (Fri), 07:30-08:00 | Room B
Chairperson(s)
Speaker(s)
  • Refining Evidence-Based Strategies in UC Practice: Positioning
     Dong Hyun Kim Chonnam National University
    Korea

Day 2 – June 26 (Fri)

Breakfast with Master 2 Sequential Treatment in Ulcerative Colitis June 26 (Fri), 07:30-08:00 | Room C
Chairperson(s)
Speaker(s)
  • The Current Role of Filgotinib in Ulcerative Colitis
     Fumihito Hirai Fukuoka University
    Japan

Day 2 – June 26 (Fri)

Breakfast with Master 3 Start Strong in Ulcerative Colitis with Upadacitinib June 26 (Fri), 07:30-08:00 | Room D
Chairperson(s)
Speaker(s)
  • When Time Matters in Ulcerative Colitis: Upadacitinib for Urgent Disease Control
     Dong Hoon Baek Pusan National University
    Korea
  • Connecting the Dots: Evidence to Insight with Upadacitinib
     Sang-Bum Kang The Catholic University of Korea
    Korea

Day 2 – June 26 (Fri)

Breakfast with Master 4 Transforming Bowel Preparation Strategies in IBD: A Change in Perspective Toward Mini Oral Sulfate Tablets June 26 (Fri), 07:30-08:00 | Room E
Chairperson(s)
Speaker(s)
  • Transforming Bowel Preparation Strategies in IBD: A Change in Perspective Toward Mini Oral Sulfate Tablets
     Jaeseung Soh Hallym University
    Korea

Day 2 – June 26 (Fri)

Breakfast with Master 5 New and Now: Introducing Etrasimod in Ulcerative Colitis June 26 (Fri), 07:30-08:00 | Room F
Chairperson(s)
Speaker(s)
  • Etrasimod in Ulcerative Colitis: Clinical Evidence and Its Role in Therapy
     David T. Rubin University of Chicago
    USA

Day 2 – June 26 (Fri)

Clinical Symposium 2 (ADT) Advanced IBD Therapies: Beyond Competition, Toward Optimization June 26 (Fri), 08:30-10:00 | Room A
Chairperson(s)
Speaker(s)
  • Anti-TNF Therapy: Still Standing Strong and Getting Smarter
     Byong Duk Ye University of Ulsan
    Korea
  • Anti-Integrin Therapy: Ensuring Safety, Enhancing Efficacy
     Vipul Jairath Western University
    Canada
  • IL-23 Inhibitors: Navigating the Expanding Choices in IBD Care
     Silvio Danese University Vita-Salute San Raffaele
    Italy
  • JAK Inhibitors and S1P Receptor Modulators: Emerging Contenders Beyond Biologics
     Taku Kobayashi Kitasato University
    Japan

Day 2 – June 26 (Fri)

Clinical Symposium 3 (Big Data) Transforming IBD Research Through Big Data and Large Cohort Studies June 26 (Fri), 08:30-10:00 | Room B
Chairperson(s)
Speaker(s)
  • Seeing Patterns, Shaping Care: The Evolution of Big Data in IBD Research
     Gilaad G. Kaplan University of Calgary
    Canada
  • Real-World Data in Action: Unlocking Insights from the Korean National Claims Data
     Hyuk Yoon Seoul National University
    Korea
  • Nationwide Big Data Insights into the Epidemiology and Trends of IBD in Taiwan
     Shu-Chen Wei National Taiwan University
    Chinese Taipei
  • Toward Prevention: Expanding Perspectives on Early-Life and Environmental Risk Factors
     Sun-Ho Lee University of Toronto
    Canada

Day 2 – June 26 (Fri)

Translational Symposium (Microbiome/Omics) Microbiome & Omics in IBD: Translating Science into Care June 26 (Fri), 08:30-10:00 | Room C
Chairperson(s)
Speaker(s)
  • Microbial Signatures in IBD: Toward Precision Diagnosis and Subtype Stratification Through Multi-Layer Biomarker Discovery
     Chang Kyun Lee Kyung Hee University
    Korea
  • Shaping the Gut Microbiome: Therapeutic Interventions and Clinical Implications for Inflammatory Bowel Disease
    Hong Koh Yonsei University
    Korea
  • Microbiota-Mediated Intestinal Fibrosis In Crohn’s Disease : From Correlation To Causality
     Ren Mao Sun Yat-sen University
    China
  • Microbes as Targets, Mediators, and Predictors of Therapy Response in IBD
     Eytan Wine The Hospital for Sick Children
    Canada

Day 2 – June 26 (Fri)

Clinical Symposium 4 (Colorectal Neoplasm) Toward Precision Colorectal Cancer Screening: Integrating Risk, Tools, and Innovation June 26 (Fri), 08:30-10:00 | Room D
Chairperson(s)
Speaker(s)
  • FIT or Colonoscopy: What Is the Best Strategy for CRC Screening?
     Wen-Feng Hsu National Taiwan University
    Chinese Taipei
  • Personalized Screening Strategies: Beyond Age-Based CRC Guidelines
     Jae Myung Cha Kyung Hee University
    Korea
  • Revolutionizing Biomarkers in Colorectal Cancer Screening
     Francis K.L. Chan The Chinese University of Hong Kong
    Hong Kong, China
  • Risk-Adapted Surveillance after Polypectomy & ESD: Who, When, and How
     Su Young Kim Yonsei University
    Korea

Day 2 – June 26 (Fri)

AOCC Plenary Session June 26 (Fri), 11:20-12:10 | Room A
Chairperson(s)
Speaker(s)
  • Mesenteric Inflammation-Associated Fibroblasts Drive Intestinal Barrier Dysfunction and Promote Crohn’s Disease Progression
     Jihye Park Ewha Womans University
    Korea
  • Integrated Metabolomic and Genetic Analyses Reveal Loss of Protective Docosahexaenoic Acid as a Key Driver Linking Ultra-Processed Food to Crohn’s Disease Risk
     Jie Chen The Third Xiangya Hospital of Central South University
    China
  • Childhood Exposure to a Sibling with Crohn’s Disease Alters Gut Microbiome and Increases Crohn’s Disease Susceptibility
     Rirong Chen University of Toronto
    Canada
  • Efficacy and Safety of Obefazimod in Moderately to Severely Active Ulcerative Colitis: Pooled Phase 3 Results From ABTECT Trials, Including a Japan and Korea Subgroup Analysis
     Tadakazu Hisamatsu Kyorin University
    Japan

Day 2 – June 26 (Fri)

Luncheon Symposium 2 Beyond Similarity: Clinical and Real-World Insights into Ustekinumab Biosimilars June 26 (Fri), 12:20-13:00 | Room B
Chairperson(s)
Speaker(s)
  • What is Same and Different? : Clinical Value of Ustekinumab Biosimilar
     Eun Soo Kim Kyungpook National University
    Korea
  • From Evidence to Experience: Real-World Application of Ustekinumab Biosimilar in Inflammatory Bowel Disease
     Sang Hyoung Park University of Ulsan
    Korea

Day 2 – June 26 (Fri)

Luncheon Symposium 3 Evolving IBD Care in the Era of IL-23 Inhibitor June 26 (Fri), 12:20-13:00 | Room C
Chairperson(s)
Speaker(s)
  • Unmet Needs in Korean IBD Care: Evolving Expectations for New Therapeutic Options
    Seong-Joon Koh Seoul National University
    Korea
  • Advancing IBD Care with Guselkumab: Insights from Clinical and Real World Evidence
     David T. Rubin University of Chicago
    USA

Day 2 – June 26 (Fri)

Luncheon Symposium 4 Fast-Acting, Long-Lasting Control: Upadacitinib in IBD June 26 (Fri), 13:00-13:40 | Room B
Chairperson(s)
Speaker(s)
  • Optimizing Treatment Strategies in Ulcerative Colitis with Upadacitinib
     Byong Duk Ye University of Ulsan
    Korea
  • Shaping a New Paradigm in Crohn’s Disease Management: The Role of Upadacitinib
     Edward V. Loftus Jr. Mayo Clinic College of Medicine and Science
    USA

Day 2 – June 26 (Fri)

Luncheon Symposium 5 A New Era in IBD Treatment: Optimizing Infliximab Therapy June 26 (Fri), 13:00-13:40 | Room C
Chairperson(s)
Speaker(s)
  • Real-World Experience with Subcutaneous Infliximab: Updated Global Evidence
    Silvio Danese University Vita-Salute San Raffaele
    Italy
  • Personalizing IBD Treatment: The Role of Therapeutic Drug Monitoring in Infliximab Therapy
     Sung Noh Hong Sungkyunkwan University
    Korea

Day 2 – June 26 (Fri)

IMKASID for Young Researchers June 26 (Fri), 14:30-16:00 | Room G
Chairperson(s)
Speaker(s)
  • Optimizing IBD Outcomes Across the Lifespan: Differential Positioning of Biologics and Small Molecules from Pediatrics to Adulthood
     Junghyun Noh Seoul National University
    Korea
  • Clinical Characteristics and Surgical Outcomes of Adolescent-Onset Crohn’s Disease Compared with Pediatric- and Adult-Onset Disease A Nationwide Multicenter Retrospective Cohort Study (CONNECT Study Group)
     Soojin Kang Ewha Womans University
    Korea
  • Clinical Characteristics and Surgical Outcomes of Adolescent-Onset Crohn’s Disease Compared with Pediatric- and Adult-Onset Disease A Nationwide Multicenter Retrospective Cohort Study (CONNECT Study Group)
     Minjee Kim Sungkyunkwan University
    Korea
  • Tailoring Colorectal Cancer Screening for Older Adults: Strategies Beyond Routine Colonoscopy
     Geunhyuk Choi Soonchunhyang University
    Korea
  • New Colorectal Cancer Screening ? Moving Beyond Fit
    Yeojin Lee University of Ulsan
    Korea
  • Artificial Intelligence in Capsule Endoscopy: Current Landscape and Future Perspectives
     Kwangmin Joo Dong-A University
    Korea
  • Gut Microbiome in Inflammatory Bowel Disease: From Dysbiosis to Personalized Therapy
     Hee Won Kwon Kyungpook National University
    Korea

Day 2 – June 26 (Fri)

Meet the Expert 1 Advancing IBD Care with Subcutaneous Infliximab June 26 (Fri), 15:50-16:20 | Exhibition
Speaker(s)
  • Redefining IBD Treatment Strategies: The Role of Subcutaneous Infliximab
     Rupert Leong University of Sydney
    Australia

Day 2 – June 26 (Fri)

Meet the Expert 2 Emerging Treatment in Crohn’s Disease with Fistula June 26 (Fri), 15:50-16:20 | Exhibition
Speaker(s)
  • Clinical Efficacy and Real World Experience with Guselkumab in CD with Fistula
     Vipul Jairath Western University
    Canada

Day 2 – June 26 (Fri)

Clinical Symposium 5 (Pregnancy & Obesity) Global IBD Perspectives: Pregnancy and Obesity across East and West June 26 (Fri), 16:20-17:50 | Room A
Chairperson(s)
Speaker(s)
  • Pregnancy in IBD: Essential Knowledge for Clinicians and Patients
     Joana Torres University of Lisbon
    Portugal
  • IBD and Pregnancy in East Asia: Regional Insights and Clinical Experience
     Eun Mi Song Ewha Womans University
    Korea
  • Epidemiology and Pathophysiology of Obesity and IBD: Asian Perspectives
     Jaeyoung Chun Yonsei University
    Korea
  • Optimizing Medical Therapy in IBD Patients with Obesity
     Siddharth Singh Mayo Clinic Arizona
    USA

Day 2 – June 26 (Fri)

Clinical Symposium 6 (Small Bowel & Nutrition) Current Perspective on Diet and Nutrition in IBD June 26 (Fri), 16:20-17:50 | Room B
Chairperson(s)
Speaker(s)
  • Dietary and Environmental Risk Factors in IBD: Theory and Practice
     Rupa Banerjee AIG Hospitals
    India
  • Impact of Diet and Urban Environment in Crohn’s Disease: Diet-omics Cohort Study
     Rui Feng Sun Yat-Sen University
    China
  • Tools and Challenges of Dietary Assessment in IBD and Colorectal Diseases: Lessons From Clinical Experiences
     Yun Jeong Lim Dongguk university
    Korea
  • Recent Advances in ENTERAL Nutrition for IBD: Beyond THE WALLS
     Robert V Bryant The Queen Elizabeth Hospital
    Australia

Day 2 – June 26 (Fri)

KASID-GEST Joint Symposium Current Status and Future Perspectives in Intestinal Diseases June 26 (Fri), 16:20-17:50 | Room C
Chairperson(s)
Speaker(s)
  • Current Status and Treatment Trends of IBD in Taiwan
     Tzung-Jiun Tsai Kaohsiung Veterans General Hospital
    Chinese Taipei
  • Current Status and Treatment Trends of IBD in Korea
     Joo Hye Song Konkuk University
    Korea
  • Current Status and Treatment Trends of Colorectal Cancer in Taiwan
     Li-Chun Chang National Taiwan University
    Chinese Taipei
  • Current Status and Treatment Trends of Colorectal Neoplasms in Korea
     Seong-Jung Kim Chosun University
    Korea

Day 2 – June 26 (Fri)

Clinical Symposium 7 (AOCC for Pediatricians) Bridging Evidence and Practice in Pediatric IBD June 26 (Fri), 16:20-17:50 | Room D
Chairperson(s)
Speaker(s)
  • Early-Onset Pediatric IBD: From Immune Pathways to Clinical Application
     Takashi Ishige Gunma University
    Japan
  • Pediatric Ulcerative Colitis: Key Updates from the Latest ECCO?ESPGHAN Guidelines
     Eytan Wine The Hospital for Sick Children
    Canada
  • Real-World Practice of Nutritional Therapy in Pediatric Crohn’s Disease
     Hyeji Lim Yonsei University
    Korea
  • Practical Precision Medicine in Pediatric IBD: Advanced Therapies in Real-World Settings
    Mi Jin Kim Sungkyunkwan University
    Korea
Hosted by
  • AOCC
  • KASID
Supported by
Korea Tourism Organization Seoul Metropolitan Government
Blue
Diamond
한국애브비
삼성바이오에피스
셀트리온제약
한국존슨앤드존슨
Diamond
한국다케다제약
Gold
한국페링제약
대웅제약
Silver
한국화이자제약
한국에자이
(주)유한양행
GSK